‘Michael’ Crosses $977 Million Worldwide, Toppling ‘Oppenheimer’ as the Highest-Grossing Biopic Ever

Lionsgate’s Michael, the Antoine Fuqua-directed dramatisation of the life of Michael Jackson, has crossed $977 million at the worldwide box office, Variety reported on 28 June 2026. The film has now overtaken Christopher Nolan’s 2023 Oppenheimer to become the highest-grossing biopic ever released.

The milestone lands in a genre that has spent the last decade cycling between prestige awards plays and event-tentpole releases, and it is a reminder that the biopic, when it gets the subject right and the soundtrack wrong, can still move like a Marvel picture. What Michael appears to have done is collapse the distance between the music video and the feature — the catalogue is the movie, and the movie, in effect, is a long-form music video that happens to have a tragic arc.

How the number got there

The $977 million figure, recorded by Variety on 28 June 2026, reflects cumulative theatrical receipts since the film’s release. Oppenheimer, which held the previous record, was itself a surprise: a three-hour, R-rated, dialogue-heavy period piece about J. Robert Oppenheimer and the Manhattan Project, distributed by Universal and tied to Nolan’s long-standing relationship with IMAX. That it was the high-water mark says something about how rarely the biopic escapes its own gravitational pull toward awards-season sobriety.

Michael breaks that pattern by leaning into the showmanship rather than away from it. Fuqua, whose résumé runs from Training Day to the Equalizer franchise, has framed the film less as a forensic biography and more as a performance-driven spectacle built around the songs. The strategy appears to have worked: the catalogue travels, and the catalogue is global.

What the framing misses

A biopic that grosses like this is never just a film. It is also a verdict, of sorts, on how the culture has decided to treat its subject in this particular moment. Michael Jackson remains a polarising figure — adored for the music, contested for nearly everything else — and the box office does not settle those questions. It does something cruder: it measures appetite. The appetite, judging by $977 million, is enormous.

There is a counter-reading worth naming. A film whose commercial success depends substantially on the music catalogue of the person it depicts is, in part, monetising a backlist. The Jackson estate, which controls the publishing and masters, sits in a structurally advantageous position that most biopic subjects cannot replicate. Bohemian Rhapsody ran on a similar dynamic with Queen’s catalogue; Straight Outta Compton did something adjacent with the relevant masters and publishing. The biopic as a format has been quietly tilting toward subjects whose estates can license a soundtrack that does half the marketing for the studio.

The structural read

What we are watching, in other words, is the convergence of two industries. The Hollywood biopic has spent fifteen years trying to find a commercially reliable formula after the Walk the Line / Ray era ran its course. The catalogue-driven event film — built around a legacy artist whose songs still clear sync licences and streaming thresholds — has, in the meantime, become one of the few theatrical propositions that can beat the superhero fatigue cycle. Michael sits at the intersection. So did Bohemian Rhapsody. So, in a different register, did Elvis.

This is not a guarantee that the model scales. Catalogue economics are unevenly distributed. There are perhaps a few dozen artists whose music can underwrite a global marketing push in 2026; everyone else is competing for the same oxygen. What the Michael number suggests is that, for the very top tier of catalogue, the theatrical biopic is no longer a prestige side bet. It is a release strategy in its own right.

Stakes

For Lionsgate, the upside is obvious: a profit participant in a $977 million title reshapes the studio’s calendar and gives its distribution arm something to point at when negotiating its 2027 slate. For the broader industry, the question is whether other studios now green-light biopics they would previously have killed in development on the assumption that the format could not clear $500 million without a Marvel logo attached.

The losers, as ever, are the mid-budget adult dramas that get squeezed when a tentpole absorbs the screens and the oxygen. The biopic in its prestige form — character-driven, two-hour, no set-piece every eight minutes — was already a hard sell theatrically. Michael does not improve its odds.

What remains genuinely uncertain is the long tail. The Variety reporting confirms the cumulative gross and the record, but does not detail the production budget, the marketing spend, or the profit-participant structure, all of which will determine whether Michael is a windfall or a break-even dressed up as a hit. Nor is there yet a public read on the critical consensus around the film itself — only the box office, which is a measure of interest, not of merit.

Desk note: Monexus framed the milestone as a story about the convergence of the biopic genre and catalogue economics, rather than as a straight celebrity tribute. The Variety wire provides the box-office figure and the comparison title; the structural argument is Monexus’s own, drawn from the broader pattern of catalogue-driven event films.